11:06:57 PM

LHDX Stock News

LHDX - Lucira Health Inc

03/28/23 8:05 AM

Nasdaq : LHDX

covid-19

Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process

Combination Test Also Secures Point-Of-Care Authorization in Australia Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription

RHEA-AI

very positive

02/27/23 8:00 AM

Nasdaq : LHDX

covid-19

Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing

Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast,

RHEA-AI

neutral

02/22/23 5:15 PM

Nasdaq : LHDX

Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology

RHEA-AI

neutral

01/05/23 9:00 AM

Nasdaq : LHDX

partnership

SESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAM

Sesame , the company building a radically new healthcare system

RHEA-AI

very positive

01/04/23 7:00 AM

Nasdaq : LHDX

covid-19

Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in Canada

For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a test Lucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs.

RHEA-AI

very positive

01/03/23 7:00 AM

Nasdaq : LHDX

covid-19

Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test

Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.

RHEA-AI

neutral

11/22/22 4:02 PM

Nasdaq : LHDX

covid-19

Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit

RHEA-AI

neutral

11/17/22 7:03 AM

Nasdaq : LHDX

Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and

RHEA-AI

neutral

11/14/22 4:02 PM

Nasdaq : LHDX

Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial

RHEA-AI

neutral

11/01/22 7:00 AM

Nasdaq : LHDX

earnings

Lucira Health to Announce Third Quarter 2022 Financial Results

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect

RHEA-AI

neutral

1 2 3 4 5 6 Next